Related Experiment Video
Updated: Jan 13, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
RAGE Cytosolic Partner Diaph1 Does Not Play an Essential Role in Diabetic Peripheral Neuropathy Progression
Kamila Zglejc-Waszak1, Bernard Kordas2, Agnieszka Korytko2
1Department of Anatomy and Histology, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-085 Olsztyn, Poland.
Abstract:
Receptor for advanced glycation end-products (RAGE) activation by hyperglycemia-induced AGE (advanced glycation end-products) accumulation is likely to play a crucial role in the development of complications such as diabetic peripheral neuropathy (DPN). RAGE signaling is mediated via its cytosolic tail. Through its cytosolic tail, RAGE recruits diaphanous-related formin 1 (Diaph1), a protein involved in actin filament organization. Disruption of RAGE-Diaph1 interactions using small molecules alleviates diabetic complications in mice; however, the role of Diaph1 in DPN progression has not been rigorously tested. In this study, we employed a Diaph1 knockout mouse (DKO) to investigate the role of Diaph1 in DPN progression. Herein, we demonstrate that, at the systemic level, CRISPR deletion of Diaph1 fails to ameliorate diabetes-induced weight loss in mice. Within the sciatic nerve (SCN), the lack of Diaph1 failed to prevent hyperglycemia-induced loss of β-actin in the nerve fibers. At a morphological level, the lack of Diaph1 leads to a partial rescue in DPN. While we observed improvements in axonal and fiber diameters in diabetic DKO mice, the g-ratio (an indicator of myelination) and myelin invaginations displayed incomplete rescue. Furthermore, the lack of Diaph1 failed to rescue motor or sensory nerve conduction defects resulting from hyperglycemia over 6 months. Overall, our data thus indicate that the complete loss of Diaph1 is insufficient to halt the progression of DPN. However, across a range of parameters including blood glucose levels, body weight measurements, axon and fiber diameters, and nerve conduction velocity, DKO diabetic mice show improvement when compared to wild-type diabetic mice.
Insights
Complete loss of Diaphanous-related formin 1 (Diaph1) does not fully prevent diabetic peripheral neuropathy (DPN) in mice. While Diaph1 knockout mice showed some improvements, nerve damage and function deficits persisted, indicating Diaph1 is insufficient alone to halt DPN progression.
Area of Science:
- Neuroscience
- Endocrinology
- Molecular Biology
Background:
- Diabetic peripheral neuropathy (DPN) is a complication linked to Receptor for Advanced Glycation End-products (RAGE) activation.
- RAGE signaling involves diaphanous-related formin 1 (Diaph1), a protein crucial for actin organization.
- Previous studies suggest disrupting RAGE-Diaph1 interactions may alleviate diabetic complications.
Purpose of the Study:
- To investigate the role of Diaph1 in the progression of diabetic peripheral neuropathy.
- To determine if complete Diaph1 deficiency can prevent or ameliorate DPN in a mouse model.
Main Methods:
- Utilized a Diaph1 knockout mouse (DKO) model to study DPN.
- Assessed systemic effects (weight loss) and sciatic nerve (SCN) changes, including β-actin levels, axonal/fiber diameters, g-ratio, and myelin integrity.
- Evaluated motor and sensory nerve conduction velocities over six months.
Main Results:
- CRISPR deletion of Diaph1 did not prevent diabetes-induced weight loss.
- Diaph1 deficiency failed to prevent hyperglycemia-induced loss of β-actin in sciatic nerve fibers.
- Partial morphological rescue was observed in DPN, with improved axonal/fiber diameters but incomplete recovery of g-ratio and myelin.
- Diaph1 knockout did not rescue motor or sensory nerve conduction defects.
Conclusions:
- Complete loss of Diaph1 is insufficient to halt the progression of diabetic peripheral neuropathy.
- DKO diabetic mice exhibited some improvements compared to wild-type diabetic mice in parameters like body weight and nerve morphology.
- Further research is needed to understand the complex mechanisms underlying DPN and identify effective therapeutic targets.

